



Recombinant Protein Technical Manual  
Recombinant Human Mesothelin/MSLN Protein (His  
Tag)  
RPES1049

Product Data:

**Product SKU:** RPES1049

**Size:** 50µg

**Species:** Human

**Expression host:** HEK293 Cells

**Uniprot:** Q13421-2

Protein Information:

**Molecular Mass:** 28.2 kDa

**AP Molecular Mass:** 33 kDa

**Tag:** C-His

**Bio-activity:**

**Purity:** > 90 % as determined by reducing SDS-PAGE.

**Endotoxin:** < 1.0 EU per µg of the protein as determined by the LAL method.

**Storage:** Lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

**Shipping:** This product is provided as lyophilized powder which is shipped with ice packs.

**Formulation:** Lyophilized from sterile PBS, pH 7.4

**Reconstitution:** Please refer to the printed manual for detailed information.

**Application:**

**Synonyms:** Megakaryocyte potentiating factor; mesothelin; Pre-pro-megakaryocyte-potentiating factor; soluble MPF mesothelin related protein;CAK1; MPF; MSLN; SMR; CAK1; CAK1 antigen

## Immunogen Information:

**Sequence:** Met 1-Arg286

## Background:

Megakaryocyte potentiating factor belongs to the mesothelin family. This family is comprised by several mammalian pre-pro-megakaryocyte potentiating factor precursor (MPF) or mesothelin proteins. Mesothelin is a glycosylphosphatidylinositol-linked glycoprotein highly expressed in mesothelial cells, mesotheliomas, and ovarian cancer, but the biological function of the protein is not known. Megakaryocyte potentiating factor is highly expressed in mesotheliomas, ovarian cancers, and some squamous cell carcinomas (at protein level). It interacts with MUC16 and potentiates megakaryocyte colony formation in vitro. Megakaryocyte potentiating factor is secreted by several mesothelioma cell lines and is frequently elevated in the blood of patients with mesothelioma. Measurement of this protein may be useful in following the response of mesothelioma to treatment.